 "medicine, drug, antibiotic, doctor, pharmaceuticals")
Shares of two pharmaceutical companies Lupin (Rs 810) and Glenmark Pharmaceuticals (Rs 550) hit their respective 52-week lows on the BSE in intra-day trade in an otherwise firm market.
In the past one month, the market price of Lupin fell by 23%, while of Glenmark Pharmaceuticals by 12% on account of negative news flow from the US health regulator. By comparison, the S&P BSE Sensex was down 2% during the same period.
On November 7, Lupin said that the US Food and Drug Administration (USFDA) had issued a warning letter to the company against a violation of current
In the past one month, the market price of Lupin fell by 23%, while of Glenmark Pharmaceuticals by 12% on account of negative news flow from the US health regulator. By comparison, the S&P BSE Sensex was down 2% during the same period.
On November 7, Lupin said that the US Food and Drug Administration (USFDA) had issued a warning letter to the company against a violation of current
